Menlo Park, CA’s 5AM Ventures has pieced together a fourth fund, a $250 million venture capital fund, to put to work in more early-stage biotech companies.
The capital was raised from a broad range of existing and new institutional investors including endowments, family offices, foundations, funds-of-funds and pension funds.
Created by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands-on approach to company building. 5AM portfolios are well diversified, including innovative platform technologies, spinouts from established life science companies, and companies developing near-term products. 5AM will continue to target early-stage life science companies with most of its investments focused on the discovery and development of novel therapeutics.
5AM’s investment team consists of Managing Partners John Diekman, Ph.D., Scott Rocklage, Ph.D., and Andy Schwab; Venture Partners Mason Freeman, M.D., Richard Ulevitch, Ph.D. and Jim Young, Ph.D.; Principals Mark Colella, Kevin Forrest, Ph.D. and Kush Parmar, M.D., Ph.D., General Counsel & COO Paul Stone, J.D. and Vice President, Finance, Jenny Lee.
Tags: Venture Capital, Venture Capital firm, Venture Capital group, Venture Capital industry, Venture Capital investment, Venture Capital Investor, Venture Capital fund, VC Funding, VC, Menlo Park Venture Capital, CA Venture Capital, Menlo Park, CA, 5AM, 5AM Ventures, Early-Stage Biotech Companies, Endowments, Family Offices, Foundations, Funds-Of-Funds, Pension Funds, Venture Capitalists, John Diekman, Scott Rocklage, Andy Schwab, Mason Freeman, Richard Ulevitch, Jim Young, Mark Colella, Kevin Forrest, Kush Parmar, Paul Stone, Jenny Lee.